Nicole Pfarr, Karin von Schwarzenberg, Dario Zocholl, Sabine Merkelbach-Bruse, Janna Siemanowski, Eva-Maria Mayr, Sylvia Herold, Karsten Kleo, Lukas C Heukamp, Eva-Maria Willing, Michael Menzel, Ulrich Lehmann, Stephan Bartels, Shounak Chakraborty, Gustavo Baretton, Melanie C Demes, Claudia Döring, Daniel Kazdal, Jan Budczies, Roland Rad, Peter Wild, Yann Christinat, Thomas McKee, Peter Schirmacher, David Horst, Reinhard Büttner, Albrecht Stenzinger, Jalid Sehouli, Claudia Vollbrecht, Michael Hummel, Elena I Braicu, Wilko Weichert
PURPOSE: Poly(ADP-ribose) polymerase inhibitors (PARPi) have shown promising clinical results in the treatment of ovarian cancer. Analysis of biomarker subgroups consistently revealed higher benefits for patients with homologous recombination deficiency (HRD). The test that is most often used for the detection of HRD in clinical studies is the Myriad myChoice assay. However, other assays can also be used to assess biomarkers, which are indicative of HRD, genomic instability (GI), and BRCA1 / 2 mutation status...
March 2024: JCO Precision Oncology